Keyword Search Results for "atrial fibrillation"

Morello, A., Lloyd-Jones, D. M., Chae, C. U., van Kimmenade, R. R., Chen, A. C., Baggish, A. L., O'Donoghue, M., Lee-Lewandrowski, E., Januzzi, J. L., Jr. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study Am Heart J. 2007;153(1):90-7. Abstract

McLean, D. S., Ravid, S., Blazing, M., Gersh, B., Shui, A., Cannon, C. P. Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials Am Heart J. 2008;155(2):298-302. Abstract

Ruff, C. T., Braunwald, E. Will warfarin ever be replaced? J Cardiovasc Pharmacol Ther. 2010;15(3):210-9. Abstract

Ruff, C. T., Giugliano, R. P., Antman, E. M., Crugnale, S. E., Bocanegra, T., Mercuri, M., Hanyok, J., Patel, I., Shi, M., Salazar, D., McCabe, C. H., Braunwald, E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J. 2010;160(4):635-41. Abstract

Kohli, Payal, Laine, Loren, Kaur, Amarjot, Curtis, Sean, Cannon, Christopher P Abstract 19248: Atrial Fibrillation/Flutter Associated with Rheumatoid Arthritis vs. Osteoarthritis and the use of Etoricoxib vs. Diclofenac: Results from the MEDAL Program Circulation. 2012;126(21 Supplement):A19248.

Naccarelli, Gerald, Bhatt, Deepak L., Camm, A. J., Le Heuzey, Jean-Yves, Lombardi, Federico, Tamargo, Juan, Bozzi, Sylvie, Marchese-Roland, Catherine, for the, Artemis Investigators Abstract 15918: Switching Patients with Atrial Fibrillation from Amiodarone to Dronedarone: Results of the ARTEMIS AF Studies Circulation. 2012;126(21 Supplement):A15918.

Dogliotti, A., Paolasso, E., Giugliano, R. P. Novel Oral Anticoagulants in Atrial Fibrillation: A Meta-analysis of Large, Randomized, Controlled Trials vs Warfarin Clin Cardiol. 2013;36(2):61-7. Abstract

Dogliotti, A., Paolasso, E., Giugliano, R. P. Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients Heart. 2013;NA(NA):NA. Abstract

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-104. Abstract

Gupta, D. K., Shah, A. M., Giugliano, R. P., Ruff, C. T., Antman, E. M., Grip, L. T., Deenadayalu, N., Hoffman, E., Patel, I., Shi, M., Mercuri, M., Mitrovic, V., Braunwald, E., Solomon, S. D., for the Effective aNticoaGulation with factor x, A. next GEneration in A. F. Thrombolysis In Myocardial Infarction Echocardiographic Study Investigators Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48 Eur Heart J. 2013;NA(NA):NA. Abstract

Gupta, D.K., Shah, A., Giugliano, R., Ruff, C. T., Antman, E., Grip, L., Deenadayalu, N., Hoffman, Elaine P., Betcher, J., Patel, I., Shi, M., Braunwald, E., Solomon, S., ENGAGE AF-TIMI 48 Investigators Cardiac Structure and Function and CHADS2 Risk Score in Patients with Atrial Fibrillation: The Effective aNticoaGulation with factor xA next GEeration in AF-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) Journal of the American College of Cardiology. 2013;61(10):A237.

Murphy, S. A., Giugliano, R. P. Atrial fibrillation and prior MI: searching for balance in ischaemic and bleeding events in patients treated with fibrin-specific anticoagulants Eur Heart J. 2013;NA(NA):NA.

Nerini, E., Grip, L., Camm, A. J., Giugliano, R. P. Atrial fibrillation and the 'other drug problem': reducing non-adherence with technology Eur Heart J. 2013;NA(NA):NA.

Reed, G. W., Cannon, C. P. Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting Clin Cardiol. 2013;NA(NA):NA. Abstract

Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., Yamashita, T., Antman, E. M. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet. 2013;NA(NA):NA. Abstract

Steinberg, B. A., Beckley, P. D., Deering, T. F., Clark, C. L., Amin, A. N., Bauer, K. A., Cryer, B., Mansour, M., Scheiman, J. M., Zenati, M. A., Newby, L. K., Peacock, W. F., Bhatt, D. L., for the Society of Cardiovascular Patient, Care Evaluation and Management of the Atrial Fibrillation Patient: A Report From the Society of Cardiovascular Patient Care Crit Pathw Cardiol. 2013;12(3):107-115. Abstract

Zakeri, R., Borlaug, B. A., McNulty, S., Mohammed, S. F., Lewis, G. D., Semigran, M. J., Deswal, A., Lewinter, M., Hernandez, A. F., Braunwald, E., Redfield, M. M. Impact of Atrial Fibrillation on Exercise Capacity in Heart Failure with Preserved Ejection Fraction: A RELAX Trial Ancillary Study Circ Heart Fail. 2013;NA(NA):NA. Abstract

Gonzalez-Quesada, C. J., Giugliano, R. P. Comparison of the Phase III Clinical Trial Designs of Novel Oral Anticoagulants Versus Warfarin for the Treatment of Nonvalvular Atrial Fibrillation: Implications for Clinical Practice Am J Cardiovasc Drugs. 2014;NA(NA):NA. Abstract

Gonzalez-Quesada, C. J., Giugliano, R. P. Erratum to: Comparison of the Phase III Clinical Trial Designs of Novel Oral Anticoagulants Versus Warfarin for the Treatment of Nonvalvular Atrial Fibrillation: Implications for Clinical Practice Am J Cardiovasc Drugs. 2014;NA(NA):NA.

Mega, J. L., Giugliano, R. P. Genotype-Guided Dosing of Warfarin Clin Chem. 2014;NA(NA):NA.

Plitt, A., Giugliano, R. P. Edoxaban: Review of Pharmacology and Key Phase I to III Clinical Trials J Cardiovasc Pharmacol Ther. 2014;NA(NA):NA. Abstract

Plitt, A., Giugliano, R. P. Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation? Future Cardiol. 2014;10(2):153-5.

Reddy, P., Giugliano, R. P. The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes J Cardiovasc Pharmacol Ther. 2014;NA(NA):NA. Abstract

Ruff, C. T., Bhatt, D. L., Steg, P. G., Gersh, B. J., Alberts, M. J., Hoffman, E. B., Ohman, E. M., Eagle, K. A., Lip, G. Y., Goto, S., Reach Registry Investigators Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry Int J Cardiol. 2014;170(3):413-8. Abstract

Ruff, Christian T., Giugliano, Robert, Braunwald, Eugene, Morrow, David, Murphy, Sabina, Deenadayalu, Naveen, Jarolim, Petr, Betcher, Joshua, Shi, Minggao, Brown, Karen S., Patel, Indravadan, Mercuri, Michele, Antman, Elliott RELATIONSHIP BETWEEN DOSE, ANTI-FACTOR XA ACTIVITY, AND OUTCOMES IN PATIENTS RANDOMIZED TO EDOXABAN IN THE ENGAGE AF-TIMI 48 TRIAL Journal of the American College of Cardiology. 2014;63(12, Supplement):A329.

Vardi, M., Debidda, M., Bhatt, D. L., Mauri, L., Cannon, C. P. Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: results from a survey among US cardiologists Clin Cardiol. 2014;37(2):103-7. Abstract